.png){kind=icon}
Return
Vimseltinib: First Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-025-02191-z.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Vimseltinib (ROMVIMZA (TM)) is an orally administered kinase inhibitor that targets colony-stimulating factor 1 receptor (CSF1R), which is being developed by Deciphera Pharmaceuticals. As CSF1R activity has been identified as a contributing factor for tenosynovial giant cell tumour (TGCT), treatments targeting CSF1R have been investigated. Vimseltinib received its first approval in February 2025 in the USA for the treatment of TGCT and is under development for the treatment of chronic graft versus host disease. This article summarizes the milestones in the development of vimseltinib leading to this first approval for the treatment of adult patients with symptomatic TGCT for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
Keywords:
GIANT-CELL TUMOR
Journal
IF:
14.4
Papers:
8.4K
Citations:
2.3W
Organization
No organization information available
Cited Papers
Updated efficacy and safety of vimseltinib in patients (pts) with tenosynovial giant cell tumor (TGCT): One-year follow-up from the MOTION phase III trial.png)
ANNALS OF ONCOLOGY
ANNALS OF ONCOLOGYIF65.4
PREAI
ShareSaveShareSaveVimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trialLANCET
LANCETIF88.5
PREAI
ShareSave
Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of expertsCANCER TREATMENT REVIEWS
OAAI
CANCER TREATMENT REVIEWSIF10.5
OAAIShareSave no more
no more